Moderna Statistics
Total Valuation
Moderna has a market cap or net worth of $25.38 billion. The enterprise value is $19.22 billion.
| Market Cap | 25.38B |
| Enterprise Value | 19.22B |
Important Dates
The next estimated earnings date is Friday, July 31, 2026, before market open.
| Earnings Date | Jul 31, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Moderna has 396.79 million shares outstanding. The number of shares has increased by 1.62% in one year.
| Current Share Class | 396.79M |
| Shares Outstanding | 396.79M |
| Shares Change (YoY) | +1.62% |
| Shares Change (QoQ) | +0.77% |
| Owned by Insiders (%) | 6.65% |
| Owned by Institutions (%) | 78.84% |
| Float | 370.08M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 11.41 |
| Forward PS | 13.22 |
| PB Ratio | 3.43 |
| P/TBV Ratio | 3.51 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 8.64 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.41, with a Debt / Equity ratio of 0.18.
| Current Ratio | 2.41 |
| Quick Ratio | 2.23 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -97.46 |
Financial Efficiency
Return on equity (ROE) is -36.56% and return on invested capital (ROIC) is -66.19%.
| Return on Equity (ROE) | -36.56% |
| Return on Assets (ROA) | -13.09% |
| Return on Invested Capital (ROIC) | -66.19% |
| Return on Capital Employed (ROCE) | -27.87% |
| Weighted Average Cost of Capital (WACC) | 9.51% |
| Revenue Per Employee | $473,404 |
| Profits Per Employee | -$679,574 |
| Employee Count | 4,700 |
| Asset Turnover | 0.18 |
| Inventory Turnover | 27.59 |
Taxes
In the past 12 months, Moderna has paid $56.00 million in taxes.
| Income Tax | 56.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +150.33% in the last 52 weeks. The beta is 1.03, so Moderna's price volatility has been similar to the market average.
| Beta (5Y) | 1.03 |
| 52-Week Price Change | +150.33% |
| 50-Day Moving Average | 50.20 |
| 200-Day Moving Average | 39.22 |
| Relative Strength Index (RSI) | 74.90 |
| Average Volume (20 Days) | 6,979,367 |
Short Selling Information
The latest short interest is 57.81 million, so 14.57% of the outstanding shares have been sold short.
| Short Interest | 57.81M |
| Short Previous Month | 58.07M |
| Short % of Shares Out | 14.57% |
| Short % of Float | 15.62% |
| Short Ratio (days to cover) | 7.48 |
Income Statement
In the last 12 months, Moderna had revenue of $2.23 billion and -$3.19 billion in losses. Loss per share was -$8.16.
| Revenue | 2.23B |
| Gross Profit | -1.56B |
| Operating Income | -2.53B |
| Pretax Income | -3.14B |
| Net Income | -3.19B |
| EBITDA | -2.30B |
| EBIT | -2.53B |
| Loss Per Share | -$8.16 |
Balance Sheet
The company has $5.21 billion in cash and $1.30 billion in debt, with a net cash position of $6.16 billion or $15.52 per share.
| Cash & Cash Equivalents | 5.21B |
| Total Debt | 1.30B |
| Net Cash | 6.16B |
| Net Cash Per Share | $15.52 |
| Equity (Book Value) | 7.41B |
| Book Value Per Share | 18.66 |
| Working Capital | 3.38B |
Cash Flow
In the last 12 months, operating cash flow was -$1.47 billion and capital expenditures -$137.00 million, giving a free cash flow of -$1.60 billion.
| Operating Cash Flow | -1.47B |
| Capital Expenditures | -137.00M |
| Depreciation & Amortization | 235.00M |
| Net Borrowing | 580.00M |
| Free Cash Flow | -1.60B |
| FCF Per Share | -$4.04 |
Margins
Gross margin is -69.89%, with operating and profit margins of -113.89% and -143.55%.
| Gross Margin | -69.89% |
| Operating Margin | -113.89% |
| Pretax Margin | -141.03% |
| Profit Margin | -143.55% |
| EBITDA Margin | -103.33% |
| EBIT Margin | -113.89% |
| FCF Margin | n/a |
Dividends & Yields
Moderna does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.62% |
| Shareholder Yield | -1.62% |
| Earnings Yield | -12.59% |
| FCF Yield | -6.32% |
Analyst Forecast
The average price target for Moderna is $43.30, which is -32.30% lower than the current price. The consensus rating is "Hold".
| Price Target | $43.30 |
| Price Target Difference | -32.30% |
| Analyst Consensus | Hold |
| Analyst Count | 23 |
| Revenue Growth Forecast (3Y) | 17.69% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Moderna has an Altman Z-Score of 2.36 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.36 |
| Piotroski F-Score | 2 |